A. B. Kiselev

A. B. Kiselev

Auto-generated profile, based on publicly available information

A. B. Kiselev

Novosibirsk State Medical University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
AKA. B. Kiselev
A. B. Kiselev
VCV. A. Chaukina
V. A. Chaukina
OAO. V. Andamova
O. V. Andamova
AAA. S. Avtushko
A. S. Avtushko
EGE. V. Garshina
E. V. Garshina
Introduction. Acute respiratory viral infections are the most widespread diseases, accounting for up to 90% of all infectious pathology, which supports the relevance of optimizing the treatment of acute viral rhinosinusitis.Aim. Evaluate the dynamics of clinical symptoms of acute viral rhinosinusitis, which arose as part of an acute respiratory infection, when supplementing therapy with the drug Respero Myrtol (Pol-Boskamp GmbH and Co.KG, Germany), the active ingredient of which is myrtol standardized 120 mg in 1 capsule.Materials and methods. The dynamics of clinical symptoms of 20 cases of acute viral rhinosinusitis in comparison groups was analyzed. Traditional treatment of patients included taking propionic acid derivatives, ascorbic acid, intranasal use of decongestants and irrigation of the nasal cavity with isotonic saline solutions. Patients who have received traditional treatment are defined as a “standard therapy group”. To assess the effectiveness of therapy using standardized myrtol, 20 cases of acute viral rhinosinusitis against the background of acute respiratory viral infections with a similar severity were analyzed, in which patients received outpatient therapy with Respero Myrtol 2 capsules 3 times a day for 7 days in addition to the above treatment (the “myrtol therapy” group). The dynamics of the disease assessed: the number of days of disability before recovery, the period of normalization of body temperature in feverish patients, the need for vasoconstrictive intranasal agents after the seventh day of therapy, the period of complete relief of pain syndrome, the period of normalization of night sleep, the number of cases of bacterial superinfection and the need for systemic antibacterial therapy.The results. In the observed patients, the quality of sleep was restored faster, the pain syndrome was stopped earlier, less often there was a need for systemic antibiotics and prolonged use of intranasal decongestants. The disease proceeded with fewer days of disability.Conclusion. The study results have been shown to report the clinical efficacy of Respero Myrtol essential oils in the outpatient treatment of patients with acute rhinosinusitis.

20 November 2025 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
AKA. B. Kiselev
A. B. Kiselev
RYR. Sh. Yunusov
R. Sh. Yunusov
VCV. A. Chaukina
V. A. Chaukina
OAO. V. Andamova
O. V. Andamova
AAA. S. Avtushko
A. S. Avtushko
Introduction. Improving the effectiveness of conservative treatment of secretory otitis media (SOM) in children remains an urgent problem because of the multifactorial etiology of the disease and the continued reliance on surgical intervention. The article presents the collective experience of monitoring the course of SOM after ARI with therapy aimed at various links in the pathogenesis of the disease. Aim. To evaluate the clinical efficacy of intranasal azoximer bromide (Polyoxidonium ® , Petrovax, Russia) versus combination therapy with a mucoregulator, topical antibacterial agents, and a decongestant for the treatment of secretory otitis media in children after acute respiratory viral infection. Materials and methods. A randomized, open-label, prospective, comparative clinical study was conducted in 49 children aged 4–7 years with SOM after ARI. The study group included 23 patients who received intranasal azoximer bromide, 3 drops in each nostril three times daily for two weeks. The control group comprised 26 patients who received combination therapy: an intranasal spray containing neomycin, polymyxin, dexamethasone metabenzoate, and phenylephrine (one administration per nostril three times daily for 10 days) plus oral carbocysteine at an age-appropriate dose for two weeks. Results. During azoximer bromide treatment, the dynamics of intratympanic pressure recovery were not inferior to those with standard therapy, and SOM relapses were less frequent at 3 and 6 months. Conclusions. Age-related characteristics of local immunity in children aged 4-7 years may underlie chronic catarrhal inflammation of the mucous membrane of the auditory tube and tympanic cavity after acute respiratory viral infection. Intranasal immunocorrection with azoximer bromide resolves catarrhal inflammation of the tympanic cavity and auditory tube during SOM developing after acute respiratory viral infection.

14 July 2023 in Russian Bulletin of Otorhinolaryngology
Verified
Journal Article
Closed access
AKA.B. Kiselev
A.B. Kiselev
VCV.A. Chaukina
V.A. Chaukina
OAO.V. Andamova
O.V. Andamova
AAA.S. Avtushko
A.S. Avtushko
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить влияние сопроводительной терапии растительным лекарственным средством «Синупрет экстракт» (Bionorica SE, Германия) на продолжительность и течение периода восстановления функциональной активности слизистой оболочки полости носа после ринохирургического лечения носовой перегородки и нижних носовых раковин с последующей марлевой тампонадой. МАТЕРИАЛ И МЕТОДЫ В исследовании приняли участие 25 мужчин в возрасте 18—50 лет (основная группа), постоянные жители Новосибирской области, с диагнозом «искривление перегородки носа» длительностью не менее 2 лет, которым на клинической базе кафедры оториноларингологии ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава России выполнена риносептопластика с тампонированием полости носа марлевыми тампонами на 1 сут. Пациенты основной группы принимали лекарственное средство «Синупрет экстракт» (таблетки, покрытые оболочкой) по 1 таблетке 2 раза в день в течение 10 дней до планируемой риносептопластики и в течение 7 дней после риносептопластики. Пациенты 1-й контрольной группы (n=16) получали препарат «Синупрет» таблетки, покрытые оболочкой, в течение 10 дней до операции и 7 дней после операции по схеме 2 таблетки 3 раза в день. Пациенты 2-й контрольной группы (n=16) не получали какую-либо секретоактивную терапию в предоперационном и в послеоперационном периодах хирургической коррекции носовой перегородки. РЕЗУЛЬТАТЫ Применение растительного лекарственного средства оказало положительное влияние на функцию носового дыхания. Все исследованные показатели продемонстрировали преимущество лечебного подхода, использованного у пациентов основной группы, с применением препарата «Синупрет экстракт» (p<0,05). На 5-е сутки у пациентов основной группы исследования носовое дыхание соответствовало норме, уменьшилось коркообразование в полости носа на фоне активации секреторной функции слизистой оболочки. Определены лучшие показатели скорости мукоцилиарного транспорта слизистой оболочки полости носа у пациентов основной группы относительно показателей у пациентов контрольных групп на всех этапах исследования. Прием препарата «Синупрет экстракт» в течение 10 дней, предшествующих оперативному лечению, и 5 дней после оперативного лечения максимально способствует уменьшению коркообразования и восстановлению носового дыхания ко 2-м суткам, нормализации мукоцилиарного транспорта к 5-м суткам после марлевой тампонады полости носа. ВЫВОДЫ Ввиду широкого использования тампонирования полости носа марлевыми тампонами растительные лекарственные препараты как средства медикаментозной протекции слизистой оболочки полости носа являются востребованными в практике врача-оториноларинголога.

18 November 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
MSMikhail Svistushkin
Mikhail Svistushkin
GNG. N. Nikiforova
G. N. Nikiforova
AKA. B. Kiselev
A. B. Kiselev
VCV. A. Chaukina
V. A. Chaukina
ESE. A. Shevchik
E. A. Shevchik
PKP. A. Kochetkov
P. A. Kochetkov
Introduction. Allergic rhinitis (AR) in conjunction with acute infectious rhinosinusitis (ARS) can lead to increased inflammation and contributes to a more severe course of ARS.Aim. To study the effect of some non-sedating H1-antihistamines on the severity of clinical presentations in adult patients with ARS and underlying AR as part of routine medical practice.Materials and methods. Group 1 (75 patients) and Group 2 (85 patients) were generated through simple randomization from the patient population with ARS and underlying AR, who were prescribed benzhydryl-piperazinyl-butylmethylxanthine succinate (Teoritin® MF, 4 mg/day) or desloratadine (INN, 5 mg/day), respectively. The course of therapy was 14 days. The estimated parameters included changes in indices of nasal symptoms, rhinoscopic and non-nasal symptoms during follow-up visits, time to reach zero indices, the proportions of patients, whose symptoms reduced after 3 and 7 days of treatment, the need for the use of nasal decongestants and changes in quality of life measures.Results and discussion. During the first 3 days of treatment, nasal breathing improved in 91% (95% CI 81–96%) of patients in Group 1 vs 56% (95% CI 45–67%) in Group 2, p < 0.001; rhinorrhea was relieved in 76% (95% CI 65–85%) and 62% (95% CI 51–72%) in Groups 1 and 2, respectively. By Day 7 of treatment, complete restoration of nasal breathing was observed in 71% of patients in Group 1 (95% CI 59–80%), and in 41% (95% CI 31–52%) in Group 2 (p = 0.014); rhinorrhea was relieved in 61%(95% CI 49–72%) of patients in Group 1 and 37% (95% CI 27–48%) in Group 2, p = 0.001. Decongestants were used by 20%(95% CI 12–31%) of patients in Group 1, and by 35% (95% CI 25–47%) of patients in Group 2, p = 0.031. The between-group difference was significant in terms of duration and frequency of adjuvant therapy, p < 0.05.Conclusion. In comparison with desloratadine, it provided a more pronounced reduction of nasal and non-nasal symptoms, as well as relief of rhinoscopic signs of inflammation in a shorter time. The use of Teoritin® MF contributed to the reduction in the need (duration and frequency) for nasal decongestants.

1 January 2023 in Russian Otorhinolaryngology
Verified
Journal Article
Closed access
ESE. V. Shugakova
E. V. Shugakova
YPYu. A. Pimenova
Yu. A. Pimenova
AKA. B. Kiselev
A. B. Kiselev
AEA. N. Evstropov
A. N. Evstropov
Staphylococci are widely distributed in the environment. Most species of the genus Staphylococcus are opportunistic resident representatives of the human and animal microbiota, capable of causing diverse clinical manifestations of varying severity. The situation is aggravated by the widespread distribution of representatives of the genus Staphylococcus, which are resistant to methicillin – the first semi-synthetic penicillin – and are causative agents of community-acquired infections posing a danger to immuno-compromised people. The purpose of our study was to identify methicillin-sensitive and methicillin-resistant strains of Staphylococcus spp. on the mucous membrane of the nasal cavity and oropharynx by polymerase chain reaction. The study involved 588 people who, as part of their professional activities, should be examined for carriage of Staphylococcus aureus in the nasopharynx. As a result of the study, staphylococcus DNA was detected in 273 (46.42%) of the subjects, and methicillin-resistant strains predominated, they were detected in 227 (83.15%) people. Among them, DNA of methicillin-resistant coagulase-negative Staphylococcus spp. was found in 148 (54.21%) people, a combination of different types of methicillin-resistant staphylococci, including methicillin-resistant S. aureus and methicillin-resistant coagulase-negative Staphylococcus spp., was detected in 53 (19.41%) subjects, DNA of methicillin-resistant S. aureus in monoculture was detected in 26 (9.52%) people. DNA of methicillin-sensitive S. aureus was found in 46 (16.84%) people.

1 January 2022 in Russian Otorhinolaryngology
Verified
Journal Article
Closed access
AKA. B. Kiselev
A. B. Kiselev
RSR. O. Stanishevskii
R. O. Stanishevskii
VCV. A. Chaukina
V. A. Chaukina
OAO. V. Andamova
O. V. Andamova
AAA. S. Avtushko
A. S. Avtushko
NHNovosibirsk State Novosibirsk Regional Hospital
Novosibirsk State Novosibirsk Regional Hospital
The task of treating any disease is to improve the quality of human life. However, there is no widespread practice in clinical studies to assess the health-related quality of life before and after medical intervention. The aim of the study was to evaluate the health-related quality of life in patients with bilateral laryngeal paralysis and the impact on the quality of life of methods of therapeutic rehabilitation of respiratory function using the international standardized questionnaire SF-36 (Russian version developed and recommended by the Multinational Center for Quality of Life Research (MCQLR)). A survey of 44 patients with bilateral laryngeal paralysis after a strumectomy lasting more than 1 year was conducted twice. The first questionnaire was conducted before the rehabilitation of respiratory function, the second questionnaire was conducted 4–6 months after rehabilitation. The patients underwent rehabilitation as part of two groups: in group 1, respiratory function rehabilitation was carried out by the method of prolonged injectable relaxation of the cricoid muscle with botulinum toxin type A. In group 2, respiratory function rehabilitation was carried out with phonopedic correction by the development of respiratory techniques and drug sedation with benzodiazepine. According to the results obtained, prolonged relaxation of the cricoid muscle by a single injection of botulinum toxin type A into the thickness of the cricoid muscle improves the physical component of the quality of life associated with health by 36%, the mental component, by 50%. Phonopedic correction will improve the physical component of the quality of life by 6%, and the mental component, by 4%. The obtained result can be used in communication between the patient and the doctor at the stage of explaining the effectiveness of available methods of conservative treatment for laryngeal paralysis.